Pfizer Advances Next-Generation Pediatric Pneumococcal Vaccine After Phase 2 Data Showed Significantly Higher Serotype 3 Immune Response

Pfizer

Pfizer

PFE

0.00
  • Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric population
  • An oral presentation at ISPPD highlighted an approximately 9 to 15-fold higher serotype 3 immunogenicity response after Dose 3 and 4 in infants receiving Pfizer's 25-valent vaccine candidate (25vPnC) compared to PREVNAR 20®
  • The investigational vaccine candidate was well-tolerated with no safety concerns identified in a Phase 2 study
  • Based on these encouraging results from the Phase 2 program across serotypes and discussions with regulatory authorities, Pfizer initiated its Phase 3 25vPnC pediatric program
  • Company advances adult program to fifth generation 35-valent vaccine candidate
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.